Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user experienced no response to 5 mg oral minoxidil after 6 months, with no hair regrowth or shedding. Suggestions included trying topical finasteride, dermastamping, and addressing DHT, while some users noted that factors like aspirin or Accutane might affect results.

A 23-year-old shares insights on hair perception, emphasizing that angles and hair manipulation can alter appearance, and advises focusing on natural views. The discussion highlights the importance of hair density over hairline perfection.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A German startup, Mane Biotech, developed a head wearable device to reactivate hair follicle stem cells, sparking skepticism among users. Some users suspect it might be a scam, while others are interested in more information from the company's newsletter.

A user shared their experience using 2-deoxy-D-ribose (2dDR) for hair regrowth, noting early positive results without side effects, alongside their long-term use of minoxidil and finasteride. They mentioned 2dDR's potential effectiveness in boosting blood flow to hair follicles and its availability online.

A user is exploring Kadeso, a product with Capilia Longa™ for hair regrowth, and seeks real-world experiences, comparing it to Minoxidil and Finasteride. They are interested in results, timeframe, side effects, and the credibility of the product's founder.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The user added topical minoxidil to their finasteride regimen, resulting in healthier hair and some regrowth, especially after quitting nicotine. They experienced minimal shedding and noted improvements in hairline density, finding the treatment mostly preventative.

A 17-year-old experienced significant hair loss after switching from topical to oral minoxidil and adding finasteride. The recommendation is to return to topical minoxidil and continue with finasteride or consider dutasteride.

The user experienced side effects from ecklonia cava similar to those reported with finasteride, including depression, brain fog, anxiety, and testicular pain. Despite these issues, the user is still considering using topical finasteride in the future.

The user discusses their experience with minoxidil for hair loss, noting that drinking coffee may reduce its effectiveness. They observed better results with the liquid solution and no coffee compared to using the foam solution and drinking coffee.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.

People discuss whether it's appropriate to suggest hair loss treatments like finasteride or minoxidil to others, especially young individuals. Opinions vary, with some advocating for sharing information and others cautioning against unsolicited advice due to potential side effects and personal sensitivities.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The user has been using finasteride successfully to stop hair shedding and is considering using topical minoxidil for regrowth but is concerned about being a non-responder and potential negative effects. They are cautious about using oral minoxidil due to past heart issues and are exploring other methods like tretinoin cream and dermarolling, though they worry about possible skin damage.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

Redensyl is being discussed as a potential substitute for minoxidil for hair growth after a brand switched from minoxidil to redensyl. The user is inquiring about the effectiveness of redensyl compared to minoxidil.